Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BREASTIMMU02: Pegfilgrastim + Trastuzumab in HER2+ Breast Cancer
NCT03571633Phase 2Active, not recruiting
- Sponsor
- Centre Léon Bérard
- Start
- Aug 2018
- Primary completion
- Jan 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pegfilgrastim in HER2-positive breast cancer, sponsored by Centre Léon Bérard. Primary endpoint: Pathological Complete Response Rate at 16 weeks. Started Aug 2018; status: active, not recruiting.
02
Drugs
pegfilgrastim
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT03571633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03571633.